Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Cardiovascular Drugs and Therapy
Erschienen in:

08.08.2023 | Review Article

Direct Oral Anticoagulants: Navigating Through Clinical Challenges

verfasst von: Maria Ioannou, Elena Leonidou, Ioanna Chaziri, Angeliki Mouzarou

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Direct oral anticoagulants (DOACs) have been approved, for over a decade, by both European and American medicine agencies, for treatment and prevention of several cardiovascular conditions. Since then, an increasing amount of data has been added to the medical literature day by day, resulting in a dichotomy in selection of the appropriate agent, dosage, and duration of treatment for special populations with multiple comorbidities. Considering these issues, we have prepared a comprehensive review for the clinical practitioner, to optimize the DOAC utilization in clinical practice.

Methods

A thorough literature search and review was conducted, concerning mainly the last decade. Our review focused on the current guidelines and the most recently published studies in PubMed, Science Direct Scopus, and Google Scholar to date.

Conclusion

The purpose of this study is to provide guidance for healthcare professionals for making proper decisions when confronted with clinical challenges. Nevertheless, further research is required to establish DOAC superiority in complicated cases, where there is clinical uncertainty.
Literatur
1.
Rose DK, Bar B. Direct oral anticoagulant agents: pharmacologic profile, indications, coagulation monitoring, and reversal agents. J Stroke Cerebrovasc Dis: Off J Natl Stroke Assoc. 2018;27(8):2049–58.CrossRef
2.
Carnicelli AP, et al. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex. Circulation. 2022;145(4):242–55.PubMedPubMedCentralCrossRef
3.
4.
5.
6.
7.
8.
9.
Khan SU, et al. Dual antiplatelet therapy after percutaneous coronary intervention and drug-eluting stents: a systematic review and network meta-analysis. Circulation. 2020;142(15):1425–36.PubMedPubMedCentralCrossRef
10.
Park DY, et al. Shortening the duration of dual antiplatelet therapy after percutaneous coronary intervention for acute coronary syndrome: a systematic review and meta-analysis. Am Heart J. 2022;251:101–14.PubMedPubMedCentralCrossRef
11.
Gibson CM, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375(25):2423–34.PubMedCrossRef
12.
Cannon CP, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377(16):1513–24.PubMedCrossRef
13.
Dewilde WJM, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet (London, England). 2013;381(9872):1107–15.PubMedCrossRef
14.
Lopes RD, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380(16):1509–24.PubMedCrossRef
15.
Berteotti M, et al. Clinical impact of high platelet reactivity in patients with atrial fibrillation and concomitant percutaneous coronary intervention on dual or triple antithrombotic therapy. J Thromb Thrombolysis. 2023;55(4):667–79.PubMedPubMedCentralCrossRef
16.
Lianos I, et al. Platelet function testing in atrial fibrillation patients undergoing percutaneous coronary intervention. J Thromb Thrombolysis. 2023;55(1):42–50.PubMedCrossRef
17.
Lip GYH, et al. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace: Eur Pacing, Arrhythmias, Cardiac Electrophysiol: J Working Groups Cardiac Pacing, Arrhythmias, Cardiac Cell Electrophysiol Eur Soc Cardiol. 2019;21(2):192–3.CrossRef
18.
Angiolillo DJ, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective: 2021 update. Circulation. 2021;143(6):583–96.PubMedCrossRef
19.
Zhu H, et al. Secondary prevention of antithrombotic therapy in patients with stable cardiovascular disease at high ischemic risk: a network meta-analysis of randomized controlled trials. Front Cardiovasc Med. 2023;9:1040473.PubMedPubMedCentralCrossRef
20.
Antithrombotic Trialists’ (ATT) Collaboration, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (London, England). 2009;373(9678):1849–60.CrossRef
21.
Coppens M, et al. Synergy of dual pathway inhibition in chronic cardiovascular disease. Circ Res. 2019;124(3):416–25.PubMedCrossRef
22.
Mega JL, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366(1):9–19.PubMedCrossRef
23.
Eikelboom JW, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319–30.PubMedCrossRef
24.
Knuuti J, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–77.PubMedCrossRef
25.
Yasuda S, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med. 2019;381(12):1103–13.PubMedCrossRef
26.
Tanigawa T, et al. Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation. Drug Metab Pharmacokinet. 2013;28(1):59–70.PubMedCrossRef
27.
Renda G, et al. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease. J Am College Cardiol. 2017;69(11):1363–71.CrossRef
28.
Eikelboom JW, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369(13):1206–14.PubMedCrossRef
29.
Durães AR, et al. Usefulness and safety of rivaroxaban in patients following isolated mitral valve replacement with a mechanical prosthesis. Am J Cardiol. 2018;122(6):1047–50.PubMedCrossRef
30.
Roost E, et al. Rivaroxaban in patients with mechanical heart valves: a pilot study. Thromb Res. 2020;186:1–6.PubMedCrossRef
31.
Duraes AR, et al. Rivaroxaban versus warfarin in patients with mechanical heart valves: open-label, proof-of-concept trial-the RIWA study. Am J Cardiovasc Drugs: Drugs, Devices, Other Interv. 2021;21(3):363–71.CrossRef
32.
Ryu R, Tran R. DOACs in mechanical and bioprosthetic heart valves: a narrative review of emerging data and future directions. Clin Appl Thromb/Hemost: Off J Int Acad Clin Appl Thromb/Hemost. 2022;28:10760296221103578.CrossRef
33.
Jawitz OK, et al. Rationale and design of PROACT Xa: a randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve. Am Heart J. 2020;227:91–9.PubMedPubMedCentralCrossRef
34.
Connolly SJ, et al. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. N Engl J Med. 2022;387(11):978–88.PubMedCrossRef
35.
Vahanian A, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022;43(7):561–632.PubMedCrossRef
36.
Guimarães PO, et al. Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: insights from the ARISTOTLE trial. Clin Cardiol. 2019;42(5):568–71.PubMedPubMedCentralCrossRef
37.
De Caterina R, et al. Valvular heart disease patients on edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. J Am College Cardiol. 2017;69(11):1372–82.CrossRef
38.
Montalescot, G. “Anti-thrombotic strategy to lower all cardiovascular and neurologic ischemic and hemorrhagic events after trans-aortic valve implantation for aortic stenosis—ATLANTIS.” American College of Cardiology Virtual Annual Scientific Session (ACC 2021). 2021.
39.
Van Mieghem NM, et al. Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR. N Engl J Med. 2021;385(23):2150–60.PubMedCrossRef
40.
Guimarães HP, et al. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med. 2020;383(22):2117–26.PubMedCrossRef
41.
Durães AR, et al. Dabigatran versus warfarin after bioprosthesis valve replacement for the management of atrial fibrillation postoperatively: DAWA pilot study. Drugs R&D. 2016;16(2):149–54.CrossRef
42.
Collet JP, et al. Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial. Eur Heart J. 2022;43(29):2783–97.PubMedCrossRef
43.
Dangas GD, et al. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med. 2020;382(2):120–9.PubMedCrossRef
44.
Maniwa N, et al. Anticoagulation combined with antiplatelet therapy in patients with left ventricular thrombus after first acute myocardial infarction. Eur Heart J. 2018;39(3):201–8.PubMedCrossRef
45.
Camaj A, et al. Left ventricular thrombus following acute myocardial infarction: JACC state-of-the-art review. J Am College Cardiol. 2022;79(10):1010–22.CrossRef
46.
Kajy M, Shokr M, Ramappa P. Use of direct oral anticoagulants in the treatment of left ventricular thrombus: systematic review of current literature. Am J Ther. 2020;27(6):e584–90.PubMedCrossRef
47.
Sedhom R, et al. Use of direct oral anticoagulants in the treatment of left ventricular thrombi: a systematic review. Am J Med. 2020;133(11):1266-1273.e6.PubMedCrossRef
48.
Ibanez B, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–77.PubMedCrossRef
49.
Robinson AA, et al. Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi. JAMA Cardiol. 2020;5(6):685–92.PubMedPubMedCentralCrossRef
50.
Lip GYH, et al. Left atrial thrombus resolution in atrial fibrillation or flutter: results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J. 2016;178:126–34.PubMedCrossRef
51.
Cheng Y-Y, et al. Left atrial appendage thrombosis and oral anticoagulants: a meta-analysis of risk and treatment response. J Cardiovasc Dev Dis. 2022;9(10):351.PubMedPubMedCentral
52.
Delewi R, et al. Left ventricular thrombus formation after acute myocardial infarction. Heart (Br Cardiac Soc). 2012;98(23):1743–9.
53.
Nso N, et al. Direct oral anticoagulants (DOAC) versus warfarin for the treatment of left ventricular thrombus (LVT) in patients with or without cardiorenal comorbidities, including CKD (chronic kidney disease) and atrial fibrillation: a systematic review and meta-analysis. Circulation. 2021;144(Suppl_1):A12654–A12654.CrossRef
54.
Huang L, et al. Systematic review of efficacy of direct oral anticoagulants and vitamin K antagonists in left ventricular thrombus. ESC Heart Failure. 2022;9(5):3519–32.PubMedPubMedCentralCrossRef
55.
Condello F, et al. Direct oral anticoagulants versus vitamin K antagonists in the treatment of left ventricular thrombosis: a systematic review and meta-analysis. Minerva Cardiol Angiol. 2022;70(6):666–76.PubMed
56.
Isa WYHW, et al. Apixaban versus warfarin in patients with left ventricular thrombus: a pilot prospective randomized outcome blinded study investigating size reduction or resolution of left ventricular thrombus. J Clin Prev Cardiol. 2020;9(4):150.CrossRef
57.
Alcalai R, et al. Apixaban vs. warfarin in patients with left ventricular thrombus: a prospective multicentre randomized clinical trial. Eur Heart J Cardiovasc Pharmacother. 2022;8(7):660–7.PubMedCrossRef
58.
Abdelnabi M, et al. Comparative study of oral anticoagulation in left ventricular thrombi (No-LVT Trial). J Am College Cardiol. 2021;77(12):1590–2.CrossRef
59.
He J, et al. Rationale and design of a prospective multi-center randomized trial of EARLY treatment by rivaroxaban versus warfarin in ST-segment elevation MYOcardial infarction with Left Ventricular Thrombus (EARLY-MYO-LVT trial). Ann Transl Med. 2020;8(6):392.PubMedPubMedCentralCrossRef
60.
Shokr M, et al. Use of direct oral anticoagulants in the treatment of left ventricular thrombi: a tertiary center experience and review of the literature. Clin Case Rep. 2018;7(1):135–42.PubMedPubMedCentralCrossRef
61.
Makrides Constantinos Andreas. Resolution of left ventricular postinfarction thrombi in patients undergoing percutaneous coronary intervention using rivaroxaban in addition to dual antiplatelet therapy. BMJ case reports. 2016;2016(bcr2016217843):26.
62.
63.
Falanga A, et al. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncology Off J Eur Soc Med Oncol. 2023;34(5):452–67.
64.
Young AM, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol: Off J Am Soc Clin Oncol. 2018;36(20):2017–23.CrossRef
65.
McBane RD 2nd, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost: JTH. 2020;18(2):411–21.PubMedCrossRef
66.
Agnelli G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382(17):1599–607.PubMedCrossRef
67.
Raskob GE, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615–24.PubMedCrossRef
68.
Planquette B, et al. Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial. Chest. 2022;161(3):781–90.PubMedCrossRef
69.
Lee AYY, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146–53.PubMedCrossRef
70.
Sabatino J, et al. Direct oral anticoagulants in patients with active cancer: a systematic review and meta-analysis. JACC: CardioOncology. 2020;2(3):428–40.PubMedPubMedCentral
71.
Toyoda K. Antithrombotic therapy for pregnant women. Neurol Med Chir. 2013;53(8):526–30.CrossRef
72.
Youssef G. “Management of atrial fibrillation during pregnancy.” E-Journal of Cardiology Practice. 2019. Vol. 17, N° 15 - 17 Jul 2019
73.
Beyer-Westendorf J, et al. Safety of direct oral anticoagulant exposure during pregnancy: a retrospective cohort study. Lancet Haematol. 2020;7(12):e884–91.PubMedCrossRef
74.
Beyer-Westendorf J, Marten S, Michalski F. Outcome of NOAC exposure during pregnancy (... and the problem of event reporting...). Blood. 2015;126(23):1125.CrossRef
75.
Said S, Hernandez GT. The link between chronic kidney disease and cardiovascular disease. J Nephropathol. 2014;3(3):99–104.PubMedPubMedCentral
76.
Lau YC, et al. Atrial fibrillation and thromboembolism in patients with chronic kidney disease. J Am College Cardiol. 2016;68(13):1452–64.CrossRef
77.
Christiansen CF, et al. Kidney disease and risk of venous thromboembolism: a nationwide population-based case-control study. J Thromb Haemost: JTH. 2014;12(9):1449–54.PubMedCrossRef
78.
Rogula S, et al. Safety and efficacy of DOACs in patients with advanced and end-stage renal disease. Int J Environ Res Public Health. 2022;19(3):1436.PubMedPubMedCentralCrossRef
79.
Jain N, Reilly RF. Clinical pharmacology of oral anticoagulants in patients with kidney disease. Clin J Am Soc Nephrol: CJASN. 2019;14(2):278–87.PubMedCrossRef
80.
Kumar S, et al. Anticoagulation in concomitant chronic kidney disease and atrial fibrillation: JACC Review Topic of the Week. J Am College Cardiol. 2019;74(17):2204–15.CrossRef
81.
82.
ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010;159(3):340-347.e1.CrossRef
83.
Landman GW, Gans ROB. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2011;364(12):1178.PubMedCrossRef
84.
Connolly SJ, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.PubMedCrossRef
85.
Schulman S, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342–52.PubMedCrossRef
86.
Giugliano RP, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104.PubMedCrossRef
87.
Investigators H-VTE, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406–15.CrossRef
88.
Lopes RD, et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010;159(3):331–9.PubMedCrossRef
89.
Agnelli G, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799–808.PubMedCrossRef
90.
Steffel J, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace: Eur Pacing, Arrhythmias, Cardiac Electrophysiol: J Working Groups Cardiac Pacing, Arrhythmias, Cardiac Cell Electrophysiol Eur Soc Cardiol. 2021;23(10):1612–76.CrossRef
91.
92.
Harrington, Josephine et al. “Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF.” Circulation. 2023;147,23:1748-1757.
93.
Bohula EA, et al. Impact of Renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial. Circulation. 2016;134(1):24–36.PubMedCrossRef
94.
Yu HT, et al. Impact of renal function on outcomes with edoxaban in real-world patients with atrial fibrillation. Stroke. 2018;49(10):2421–9.PubMedCrossRef
95.
Wang Y, et al. Efficacy and safety of renal function on edoxaban versus warfarin for atrial fibrillation: a systematic review and meta-analysis. Medicines (Basel, Switzerland). 2023;10(1):13.PubMed
96.
97.
Siontis KC, et al. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation. 2018;138(15):1519–29.PubMedPubMedCentralCrossRef
98.
Miao B, et al. Rivaroxaban versus apixaban in non-valvular atrial fibrillation patients with end-stage renal disease or receiving dialysis. Eur J Haematol. 2020;104(4):328–35.PubMedCrossRef
99.
Pokorney SD, et al. Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial. Circulation. 2022;146(23):1735–45.PubMedCrossRef
100.
Reinecke H, et al. A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study. Circulation. 2023;147(4):296–309.PubMedCrossRef
101.
Strategies for the management of atrial fibrillation in patients receiving dialysis (SAFE-D). 2019. ClinicalTrials.​gov. Access 25 April 2023.
102.
Semmler G, et al. Safety of direct oral anticoagulants in patients with advanced liver disease. Liver Int: Off J Int Assoc Study Liver. 2021;41(9):2159–70.CrossRef
103.
O’Leary JG, et al. AGA clinical practice update: coagulation in cirrhosis. Gastroenterology. 2019;157(1):34-43.e1.PubMedCrossRef
104.
Qamar A, et al. Oral anticoagulation in patients with liver disease. J Am College Cardiol. 2018;71(19):2162–75.CrossRef
105.
Lawal OD, et al. Comparative effectiveness and safety of direct oral anticoagulants and warfarin in patients with atrial fibrillation and chronic liver disease: a nationwide cohort study. Circulation. 2023;147(10):782–94.PubMedCrossRef
106.
Chagnac A, et al. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol. 2000;278(5):F817–22.PubMedCrossRef
107.
Wallace JL, et al. Comparison of initial warfarin response in obese patients versus non-obese patients. J Thromb Thrombolysis. 2013;36(1):96–101.PubMedCrossRef
108.
Malik AH, et al. Impact of weight on the efficacy and safety of direct-acting oral anticoagulants in patients with non-valvular atrial fibrillation: a meta-analysis. Europace: Eur Pacing, Arrhythmias, Cardiac Electrophysiol: J Working Groups Cardiac Pacing, Arrhythmias, Cardiac Cell Electrophysiol Eur Soc Cardiol. 2020;22(3):361–7.CrossRef
109.
Martin K, et al. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost: JTH. 2016;14(6):1308–13.PubMedCrossRef
110.
Piran S, et al. Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: a retrospective study. Res Pract Thromb Haemost. 2018;2(4):684–8.PubMedPubMedCentralCrossRef
111.
Coons, James C., et al. Effectiveness and safety of direct oral anticoagulants versus warfarin in obese patients with acute venous thromboembolism. Pharmacother J Human Pharmacol Drug Ther 2020;40.3:204-210.
112.
Mhanna M, et al. Direct oral anticoagulants versus warfarin in morbidly obese patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis. Am J Ther. 2021;28(5):e531–9.PubMedCrossRef
113.
Park CS, et al. Increased risk of major bleeding in underweight §patients with atrial fibrillation who were prescribed non-vitamin K antagonist oral anticoagulants. Heart Rhythm. 2017;14(4):501–7.PubMedCrossRef
114.
Boriani G, et al. Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2019;40(19):1541–50.PubMedCrossRef
115.
Hohnloser SH, et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and extremes in body weight. Circulation. 2019;139(20):2292–300.PubMedCrossRef
116.
Lee C-H, et al. Body mass index is an independent predictor of major bleeding in non-valvular atrial fibrillation patients taking dabigatran. Int J Cardiol. 2017;228:771–8.PubMedCrossRef
Metadaten
Titel
Direct Oral Anticoagulants: Navigating Through Clinical Challenges
verfasst von
Maria Ioannou
Elena Leonidou
Ioanna Chaziri
Angeliki Mouzarou
Publikationsdatum
08.08.2023
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 3/2024
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-023-07499-0

Weitere Artikel der Ausgabe 3/2024

Influence of Genetic and Epigenetic Factors of P2Y12 Receptor on the Safety and Efficacy of Antiplatelet Drugs

  • Open Access
  • Review Article

Left Bundle Branch Area Pacing versus Biventricular Pacing for Cardiac Resynchronization Therapy on Morbidity and Mortality

  • Original Article

MicroRNA-92a in Cardiovascular Disease: An Insufficiently Explored and Controversial Research Area

  • Letter to the Editor

Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials

  • Open Access
  • Original Article

Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease

  • Open Access
  • Original Article

Effect of Remote Ischaemic Conditioning on the Inflammatory Cytokine Cascade of COVID-19 (RIC in COVID-19): a Randomized Controlled Trial

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Kardiologie

Koronare Herzkrankheit: Das waren die Top-Studien 2024

Zum Thema Koronare Herzkrankheit gab es 2024 wichtige neue Studien. Beleuchtet wurden darin unter anderem der Stellenwert von Betablockern nach Herzinfarkt, neue Optionen für eine Lipidsenkung sowie die Therapie bei infarktbedingtem kardiogenem Schock.

Kaffeegenuss sicher bei Vorhofflimmern

Menschen mit Vorhofflimmern fürchten oft, Kaffee könnte schlecht für ihr Herz sein. Solche Ängste sind offenbar unbegründet: Zwei Schweizer Untersuchungen deuten sogar auf eine reduzierte Rate von kardiovaskulären Ereignissen unter Kaffeetrinkern.

Mit jedem Defibrillationsversuch sinkt die Überlebenschance

Wie wirkt es sich auf die Prognose aus, wenn bei Herzstillstand einmal, zweimal oder gar 29 Mal geschockt werden muss? Laut einer aktuellen Studie besteht ein deutlicher Zusammenhang zwischen der Zahl der Defibrillationsversuche und den Überlebenschancen.

Mit Spenderherz von Triathlon zu Triathlon

Ein 50-Jähriger mit Spenderherz rennt, radelt und schwimmt bis zu 14 Stunden in der Woche – beim Hawaii-Triathlon erreicht er einen Platz im Mittelfeld. Sein neues Herz kann sich an die Belastung erstaunlich gut anpassen. Selbst mit 65 Jahren ist er noch ungewöhnlich fit.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise